photo
Speaker

Adelene Perkins, MBA

CHAIR & CHIEF EXECUTIVE OFFICER, INFINITY PHARMACEUTICALS, INC.
Cambridge, Massachusetts, United States
Adelene Perkins joined infinity in 2020 and serves as Infinity’s chief executive officer and Infinity’s chair, a position she has held since 2012.
Prior to Infinity, Ms. Perkins held positions at TransForm Pharmaceuticals (acquired by J&J), Genetics Institute (now a unit of Pfizer) including as chief executive officer of MetaMorphix, (a joint venture between Genetics Institute and Johns Hopkins University), and Bain & Company.
Ms. Perkins received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. In addition to chairing the Infinity (NASDAQ: INFI) Board, she is on the Boards of Bruker Corporation (NASDAQ: BRKR), Massachusetts General Hospital, BIO (Biotechnology Industry Organization), the Massachusetts Biotechnology Council, and is the vice chairman of the Board of Project Hope. She is a past member of the Boards of Padlock Therapeutics, prior to its acquisition by Bristol-Myers Squibb, and the Massachusetts Life Science Center.
Speaking In
[Available On-Demand]
Infinity is advancing eganelisib, a first-in-class, oral immuno-oncology development candidate that…